Partnering

BioNTech´s aim is to develop only first in class therapies

2016-02-16 Contract Partnering_cutA key component of BioNTech’s commercial strategy is to collaborate with partners that have a similar fascination, drive and commitment in developing and commercializing truly innovative and disruptive immunotherapies.

BioNTech is actively engaged in many collaborations, partnerships and licensing deals supporting development of first in class therapies and also benefits from a global network of academic partners, which we leverage for leading clinical opinion, scientific expertise and novel ideas, the latter of which we translate, in collaboration with our partners, into successful commercial products.

BioNTech has pharma collaborations in each of our therapeutic businesses. Our current partnerships are a testament to our ability to innovate and execute.
To learn more about partnering, licensing, collaborations, partnerships, or for any scientific inquiries, please contact:

BioNTech AG
Business Development
An der Goldgrube 12
55131 Mainz
Germany

E-Mail: partnering@biontech.de

Industry Partners

Lilly2

Strategic collaboration to develop and commercialize novel messenger RNA-based, individualized cancer vaccines

Lilly2

Licensing agreement on novel tumor targets and corresponding T-cell receptors

Sanofi_BNT_RNA

Licensing, co-development and co-commercialization agreement for mRNA cancer immunotherapies

Genmab und Bio

Co-development and commercialization agreement on bispecific antibodies

Bayer_BioNTech

Development of novel, first-in-class mRNA vaccines and therapeutics specifically for Animal Health applications

BioNTech has further a strategic partnership with Siemens to construct a fully automated, paperless and digitalized commercial cGMP-Production site for individualized vaccines.

Academic Partners

Tron2

TRON is a biopharmaceutical research organization that pursues new diagnostics and drugs for the immuno-therapeutic treatment.

CI3

CI3 is a scientific, clinical and regulatory network of over 500 scientists to advance „new to the world“ immunotherapies.

BioNTech collaborates with a large number of Universities and Medical Centers in Europe and the U.S. to conduct its ongoing clinical studies.